**NOTE: Exercise your medical judgment and discretion when providing a diagnosis and characterization of the patient’s medical condition. This template is provided for informational purposes. It is not meant to replace a prescriber’s independent medical decision-making.**

[Date]

[Medical Director]

[Payer Name]

[Address]

[City, State Zip]

Re: Medical Necessity for LOQTORZI™ (toripalimab-tpzi)

[Patient Name]

[Patient Date of Birth]

 [Patient Policy Number]

Dear [Medical Director]:

I am writing on behalf of my patient, [Patient Name] to provide information to support the medical necessity of LOQTORZI™, which is indicated:

* in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
* as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

 This letter outlines [Patient Name]’s medical history, prognosis, and treatment rationale.

**Patient’s History**

* Patient’s diagnosis, date of diagnosis
* Laboratory results and date
* Patient’s current medical condition
* Previous and current treatment history
* Patient’s response to previous treatment/therapy

**Rationale for Treatment**

Given the patient’s history, condition, and prescribing information for LOQTORZI™, I believe treatment of [Patient Name] with LOQTORZI™ is warranted, appropriate, and medically necessary.

The following documentation is enclosed:

* LOQTORZI™ full Prescribing Information
* Medical literature regarding the use of LOQTORZI™ for (insert disease)
* Relevant clinical documentation such as history and physical, progress notes, treatment history, and outcomes

Please call my office at [Phone Number] if I can provide any additional information. I look forward to receiving your timely response.

Sincerely,

[Physician Name]

[Participating Provider Number]

Enclosures [Attach FDA prescribing information for LOQTORZI™, clinical notes for this patient and medical literature.]

LOQTORZI is a trademark of Coherus BioSciences, Inc.

©2023 Coherus BioSciences, Inc. All rights reserved. 0523-COH-P709